A randomized, dose-finding and confirmatory, double-blind, placebo-controlled, parallel-group multicenter study with a 2-stage adaptive design and randomized withdrawal to evaluate the efficacy, safety, and tolerability of brivaracetam as monotherapy in patients 2 to 25 years of age with childhood absence epilepsy or juvenile absence epilepsy.